Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 11 Colorectal Neoplasms 4 Breast Neoplasms 3 Solid Tumors 2 Sarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Vulvar Neoplasms 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Neuroendocrine Tumors 1 Neoplasms 1 Liver Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioblastoma 1 Gallbladder Neoplasms 1 Disease Progression 1 Disease 1 Clear-cell metastatic renal cell carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumors 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Sorafenib 222 lenvatinib 145 Bevacizumab 129 Nivolumab 86 atezolizumab 79 pembrolizumab 75 Radiosurgery 71 durvalumab 63 Oxaliplatin 60 sintilimab 59 Fluorouracil 56 Doxorubicin 47 tislelizumab 45 apatinib 44 Radiofrequency Ablation 44 Hepatectomy 42 Leucovorin 41 camrelizumab 40 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 28 Cisplatin 28 Gemcitabine 26 Cyclophosphamide 26 cabozantinib 25 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡